Megan S Lim

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. pmc T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
    Lindsay A Schmidt
    Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:121-6. 2009
  2. pmc Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
    David R Abbott
    Department of Pathology, University of Michigan Medical School, M5242 Medical Science 1, 1301 Catherine, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:113-9. 2009
  3. doi request reprint The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
    Megan S Lim
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Blood 114:1585-95. 2009

Research Grants

  1. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2010
  2. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2011

Collaborators

Detail Information

Publications3

  1. pmc T cell lymphoproliferative disorders associated with anti-tumor necrosis factor alpha antibody therapy for ulcerative colitis: literature summary
    Lindsay A Schmidt
    Department of Pathology, M5240 Medical Science I, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:121-6. 2009
    ..The spectrum of lymphoproliferative disorders associated with infliximab and the potential mechanisms by which they occur are discussed...
  2. pmc Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule
    David R Abbott
    Department of Pathology, University of Michigan Medical School, M5242 Medical Science 1, 1301 Catherine, Ann Arbor, MI 48109 0602 USA
    J Hematop 2:113-9. 2009
    ..Our findings further elucidate the cellular mechanisms accompanying Bcl-2 inhibition and demonstrate the potential of Bcl-2 inhibitors as therapeutic agents for the treatment of non-Hodgkin lymphomas...
  3. doi request reprint The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
    Megan S Lim
    Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA
    Blood 114:1585-95. 2009
    ..Our studies carry important implications for the use of MS-driven approaches for the elucidation of neoplastic pathobiology, the identification of novel diagnostic biomarkers, and pathogenetically relevant therapeutic targets...

Research Grants2

  1. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2010
    ..Collectively, our studies will lead to identification of protein biomarkers of NPM/ALK lymphomas that will be important for the diagnostic assessment, treatment and monitoring of patients with ALCL. ..
  2. Proteomic biomarkers of ALK+ lymphoma
    Megan S Lim; Fiscal Year: 2011
    ..Collectively, our studies will lead to identification of protein biomarkers of NPM/ALK lymphomas that will be important for the diagnostic assessment, treatment and monitoring of patients with ALCL. ..